Corporate Banner
Satellite Banner
Next Gen Sequencing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Contract Research Organizations Adopt Ion Torrent Next-Generation Sequencing Platform

Published: Monday, June 02, 2014
Last Updated: Wednesday, June 04, 2014
Bookmark and Share
MolecularMD and Selah Genomics to Use Oncomine Cancer Research Panel for Clinical Trial Design.

Two Contract Research Organizations (CROs) with leading expertise in molecular testing have decided to utilize the new Oncomine Cancer Research panel, which runs on Life Technologies Ion Torrent sequencing instruments, for clinical trial analyses and design.

This comprehensive multi-biomarker assay allows concurrent analyses of DNA and RNA in one workflow, allowing researchers to simultaneously detect all four classes of tumor-driving alterations: single nucleotide variants, copy number variants, tumor suppressors and gene fusions. As CROs and their pharma partners validate their use of this new tool, the potential exists for patients to be more effectively enrolled into clinical trials and study designs made easier.

Founded in 2005 by Brian Druker, M.D., Ph.D. (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) MolecularMD Corporation develops and commercializes specialty molecular diagnostics for oncology applications across the entire oncology pharmaceutical development life cycle.

Selah Genomics is a clinical diagnostics specialist supporting early stage drug development, clinical trials and regulatory processes in the pharmaceutical industry and helping clinicians and healthcare providers to treat and monitor patients.

“We see the Oncomine Cancer Research Panel as a valuable tool in advancing MolecularMD's comprehensive companion diagnostics program, and personalized medicine in general," stated Glenn Miller, Executive Vice President and CTO of MolecularMD. "The Ion PGM platform, combined with this new panel, meets many of our needs to support drug and diagnostic regulatory submissions with specific actionable genetic markers, while generating a breadth of additional data from variants that can be used in identifying novel drug sensitivities in the future. The Oncomine Cancer Research Panel makes an excellent addition to the broad menu of services we offer to the global biopharmaceutical community.”

“Limited amounts of biopsy tissue is a key challenge in oncology – especially for lung cancer patients,” said Michael Bolick, chief executive officer of Selah Genomics, Inc . “Concurrent analysis of DNA and RNA will reduce the need for repeat biopsy and expand the availability of archived specimens needed for biomarker discovery. We are particularly keen to leverage this technology in development of a universal companion diagnostic for our pharma partners. ”

The Oncomine Cancer Research panel enables simultaneous testing of 160 known cancer genes. The panel employs Life Technologies Ion AmpliSeq chemistry, which requires a very small amount of starting material -- as little as 10 nanograms of DNA or RNA from formalin-fixed paraffin-embedded tissue -- which is often extremely limited in tumor specimens.

“Content for the Oncomine Cancer Research Panel was selected by leveraging the expertly curated data in the Oncomine Knowledgebase, a long-trusted source of oncology data for pharmaceutical companies, the translational research community, and CROs,” said Dan Rhodes, Ph.D., head of oncology strategy, life sciences solutions, for Thermo Fisher. “The combination of one of the world’s largest collection of oncology data with the rapid, simple-to-use Ion sequencing technology positions Thermo Fisher Scientific as a game-changing company in the oncology clinical research space.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ebola Sequencing Data Released to Global Research Community Online
To curb further spread of Ebola in Sierra Leone, a team of scientists that is part of an international, multi-organizational effort has released their first dataset of the virus’ genetic structure online.
Wednesday, June 03, 2015
Thermo's NGS Platform Selected for Nationwide Clinical Research Program
National Cancer Institute-MATCH trial to sequence thousands of tumor samples using Ion Torrent targeted sequencing technology.
Monday, June 01, 2015
Thermo Scientific Announces Listing of the Ion PGM Dx System
Company has completed the listing with the U.S. FDA as class II medical device.
Saturday, September 20, 2014
Biodesign Institute, Thermo Fisher Partner on $9M Radiation Test
Partnership enters a new, $9M phase of a project to produce a diagnostic test to rapidly measure an individual’s level of absorption of ionizing radiation.
Wednesday, June 04, 2014
Thermo, USDA-ARS and Penn State to Collaborate on Food Safety Testing
Industry, academic and government partners to characterize and develop rapid genetic tests for toxic E. coli species
Wednesday, May 21, 2014
Thermo Completes Life Tech Acquisition
The completion of the transaction follows the receipt of all required regulatory approvals.
Tuesday, February 04, 2014
Thermo Receives EC Clearance for Life Tech Acquisition
Thermo Fisher Scientific announced that it has received approval from the European Commission (EC) for its pending acquisition of Life Technologies Corporation.
Tuesday, November 26, 2013
Scientific News
New Virus Identified In Blood Supply
Scientists have discovered a new virus that can be transmitted through the blood supply.
Far-reaching Genetic Study of 1,000 UK People
300,000 gene variants from 1,000 people made publically available via F1000Research.
DNA Alterations as Among Earliest to Occur in Lung Cancer Development
Genetic footprints of precancer detectable in some blood samples.
Targeting DNA
Protein-based sensor could detect viral infection or kill cancer cells.
Genetic Sleuthing
Sabeti team applies Ebola methods to shed light on spread of Lassa fever.
Seeking “Gold Standard” Wastewater Treatments
Metagenomic analyses lend insights into how microbes break down wastewater contaminants.
Using Genetic Sequencing to Manage Cancer in Children
A team of scientists have investigated the feasibility of incorporating clinical sequencing information into the care of young cancer patients.
Big Data Tool to Reveal Immune System Role in Diseases
Researchers from the Icahn School of Medicine at Mount Sinai and Princeton University have designed a new online tool that predicts the role of key proteins and genes in diseases of the human immune system.
Next-Gen Genomic Tests Identify Brain-Eating Amoeba
New UCSF center aims to make tests more affordable and accessible to doctors.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos